# Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix

> **NCT03305341** · EARLY_PHASE1 · ACTIVE_NOT_RECRUITING · sponsor: **Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair** · enrollment: 20 (estimated)

## Conditions studied

- Covid19

## Interventions

- **BIOLOGICAL:** COVID-19 Therapeutic Biologic Mix - NOVAVAX COVID-19 VACCINE plus BCG Vaccine Mix for percutaneous use

## Key facts

- **NCT ID:** NCT03305341
- **Lead sponsor:** Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2025-05-18
- **Primary completion:** 2026-07-18
- **Final completion:** 2026-07-28
- **Target enrollment:** 20 (ESTIMATED)
- **Last updated:** 2025-06-11

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03305341

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03305341, "Proof-of-Concept Clinical Pharmacology Trial for COVID-19 Antigen Presentation Therapeutic Biologic Mix". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT03305341. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*